Benjamin D Goodman1, Edward M Mannina2, Sandra K Althouse3, Mary A Maluccio4, Higinia R Cárdenes5. 1. Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: bengoodman2010@gmail.com. 2. Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana. 3. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana. 4. Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana. 5. Schneck Cancer Center, Seymour, Indiana.
Abstract
PURPOSE: To evaluate long-term outcome and toxicity of stereotactic body radiation therapy (SBRT) for hepatic oligometastases from solid tumors. METHODS AND MATERIALS: Eligible patients had 1 to 3 liver metastases, maximum sum diameter 6 cm, without extrahepatic progression. We treated 106 lesions in 81 patients; 67% with colorectal primaries. Median dose was 5400 cGy in 3 to 5 fractions. RESULTS: At median follow-up of 33 months (2.5-70 months), overall local control was 94% (95% confidence interval, not estimable); Kaplan-Meier estimated 96% at 1 year and 91% at 2, 3, and 4 years. Partial/complete response was observed in 69% of lesions with less than 3% progressing. Median survival time was 33.6 months (95% confidence interval, 29.1-38.4); Kaplan-Meier survival estimates at 1, 2, 3, and 4 years were 89.9%, 68.6%, 44.0%, and 28.0%, respectively. Grade 3 or greater liver toxicity was 4.9%. CONCLUSION: SBRT is effective for selected patients with hepatic oligometastases with limited toxicities. A phase 3 trial comparing SBRT with "gold-standard" surgical resection is warranted.
PURPOSE: To evaluate long-term outcome and toxicity of stereotactic body radiation therapy (SBRT) for hepatic oligometastases from solid tumors. METHODS AND MATERIALS: Eligible patients had 1 to 3 liver metastases, maximum sum diameter 6 cm, without extrahepatic progression. We treated 106 lesions in 81 patients; 67% with colorectal primaries. Median dose was 5400 cGy in 3 to 5 fractions. RESULTS: At median follow-up of 33 months (2.5-70 months), overall local control was 94% (95% confidence interval, not estimable); Kaplan-Meier estimated 96% at 1 year and 91% at 2, 3, and 4 years. Partial/complete response was observed in 69% of lesions with less than 3% progressing. Median survival time was 33.6 months (95% confidence interval, 29.1-38.4); Kaplan-Meier survival estimates at 1, 2, 3, and 4 years were 89.9%, 68.6%, 44.0%, and 28.0%, respectively. Grade 3 or greater liver toxicity was 4.9%. CONCLUSION: SBRT is effective for selected patients with hepatic oligometastases with limited toxicities. A phase 3 trial comparing SBRT with "gold-standard" surgical resection is warranted.
Authors: R Vera; E González-Flores; C Rubio; J Urbano; M Valero Camps; J J Ciampi-Dopazo; J Orcajo Rincón; V Morillo Macías; M A Gomez Braco; G Suarez-Artacho Journal: Clin Transl Oncol Date: 2019-07-29 Impact factor: 3.405
Authors: Joseph I Kang; Daniel C Sufficool; Chung-Tsen Hsueh; Andrew J Wroe; Baldev Patyal; Mark E Reeves; Jerry D Slater; Gary Y Yang Journal: J Gastrointest Oncol Date: 2019-02
Authors: Alicia Román-Jobacho; María Hernández-Miguel; María Jesús García-Anaya; Jaime Gómez-Millán; J A Medina-Carmona; Ana Otero-Romero Journal: J Clin Transl Res Date: 2021-05-27
Authors: Fabian Weykamp; Philipp Hoegen; Sebastian Klüter; C Katharina Spindeldreier; Laila König; Katharina Seidensaal; Sebastian Regnery; Jakob Liermann; Carolin Rippke; Stefan A Koerber; Carolin Buchele; Jürgen Debus; Juliane Hörner-Rieber Journal: Front Oncol Date: 2021-06-09 Impact factor: 6.244
Authors: Derek P Bergsma; Joseph K Salama; Deepinder P Singh; Steven J Chmura; Michael T Milano Journal: Front Oncol Date: 2017-09-19 Impact factor: 6.244